| SARS-CoV-2 BA. 1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... Science Translational Medicine 14 (645), eabn8543, 2022 | 81 | 2022 |
| SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... BioRxiv, 2021 | 42 | 2021 |
| Persistent COVID-19 symptoms at 6 months after onset and the role of vaccination before or after SARS-CoV-2 infection SA Richard, SD Pollett, AC Fries, CM Berjohn, RC Maves, T Lalani, ... JAMA network open 6 (1), e2251360-e2251360, 2023 | 40 | 2023 |
| Durability of SARS-CoV-2–specific T-cell responses at 12 months postinfection Z Lu, ED Laing, J Pena DaMata, K Pohida, MS Tso, EC Samuels, NJ Epsi, ... The Journal of Infectious Diseases 224 (12), 2010-2019, 2021 | 38 | 2021 |
| Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history W Wang, S Lusvarghi, R Subramanian, NJ Epsi, R Wang, E Goguet, ... Cell host & microbe 30 (12), 1745-1758. e7, 2022 | 37 | 2022 |
| Differential requirements of androgen receptor in luminal progenitors during prostate regeneration and tumor initiation CW Chua, NJ Epsi, EY Leung, S Xuan, M Lei, BI Li, SK Bergren, ... Elife 7, e28768, 2018 | 31 | 2018 |
| SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody magnitude is associated with age and COVID-19 severity ED Laing, NJ Epsi, SA Richard, EC Samuels, W Wang, R Vassell, ... medrxiv, 2021.04. 27.21256207, 2021 | 24 | 2021 |
| Understanding'hybrid immunity': comparison and predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19 vaccines. NJ Epsi, SA Richard, DA Lindholm, K Mende, A Ganesan, N Huprikar, ... Clin. infect. dis, 2022 | 22 | 2022 |
| Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses ED Laing, SL Sterling, SA Richard, NJ Epsi, EC Samuels, S Phogat, ... MedRxiv, 2021 | 21 | 2021 |
| Integrative (epi) genomic analysis to predict response to androgen-deprivation therapy in prostate cancer S Panja, S Hayati, NJ Epsi, JS Parrott, A Mitrofanova EBioMedicine 31, 110-121, 2018 | 19 | 2018 |
| Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) instrument in patients with coronavirus disease 2019 SA Richard, NJ Epsi, S Pollett, DA Lindholm, AMW Malloy, R Maves, ... Open Forum Infectious Diseases 8 (12), ofab517, 2021 | 17 | 2021 |
| SARS-CoV-2 infections and serologic responses among military personnel deployed on the USNS COMFORT to New York City during the COVID-19 pandemic T Lalani, TK Lee, ED Laing, A Ritter, E Cooper, M Lee, M Baker, T Baldino, ... Open Forum Infectious Diseases 8 (2), ofaa654, 2021 | 17 | 2021 |
| Understanding “hybrid immunity”: comparison and predictors of humoral immune responses to severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2) and coronavirus … NJ Epsi, SA Richard, DA Lindholm, K Mende, A Ganesan, N Huprikar, ... Clinical Infectious Diseases 76 (3), e439-e449, 2023 | 16 | 2023 |
| Clinical, immunological, and virological SARS-CoV-2 phenotypes in obese and nonobese military health system beneficiaries NJ Epsi, SA Richard, ED Laing, AC Fries, E Millar, MP Simons, C English, ... The Journal of infectious diseases 224 (9), 1462-1472, 2021 | 13 | 2021 |
| Bipotent progenitors do not require androgen receptor for luminal specification during prostate organogenesis M Shibata, NJ Epsi, S Xuan, A Mitrofanova, MM Shen Stem cell reports 15 (5), 1026-1036, 2020 | 13 | 2020 |
| Genome-wide analysis of therapeutic response uncovers molecular pathways governing tamoxifen resistance in ER+ breast cancer SM Rahem, NJ Epsi, FD Coffman, A Mitrofanova EBioMedicine 61, 2020 | 13 | 2020 |
| A betacoronavirus multiplex microsphere immunoassay detects early SARS-CoV-2 seroconversion and controls for pre-existing seasonal human coronavirus antibody cross-reactivity ED Laing, SL Sterling, SA Richard, S Phogat, EC Samuels, NJ Epsi, ... MedRxiv, 2020 | 11 | 2020 |
| pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma NJ Epsi, S Panja, SR Pine, A Mitrofanova Communications Biology 2 (1), 334, 2019 | 11 | 2019 |
| SARS-CoV-2 BA. 1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies. Sci Transl Med 14: eabn8543 S Lusvarghi, SD Pollett, SN Neerukonda, W Wang, R Wang, R Vassell, ... | 6 | 2022 |
| Predictive value of an age-based modification of the National Early Warning System in hospitalized patients with COVID-19 RC Maves, SA Richard, DA Lindholm, N Epsi, DT Larson, C Conlon, ... Open forum infectious diseases 8 (12), ofab421, 2021 | 6 | 2021 |
